Characteristics and overall survival of patients with early‐stage non‐small cell lung cancer: A cohort study in Denmark
Authors:
Open Access
- 20 June 2022
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (1) , 30-37
Abstract
Non‐small cell lung cancer (NSCLC) accounts for the majority of all lung cancer diagnoses, and approximately 35% of patients with NSCLC are diagnosed at an early stage (I–IIIA). This study aimed to describe epidermal growth factor receptor (EGFR) testing, patient characteristics, and overall survival (OS) among patients with early‐stage NSCLC in Denmark. Patients with early‐stage NSCLC registered in the Danish Lung Cancer Registry in 2013–2018 were followed through 2019. We described EGFR testing, descriptively summarised patient characteristics, and calculated OS by EGFR testing and mutation status. The association between EGFR mutation (EGFRm) and all‐cause mortality was estimated using Cox proportional‐hazards regression, in subgroups defined by stage at diagnosis, age at diagnosis, comorbidity, and receipt of surgery. In 2013–2018, 21,282 patients with NSCLC were registered in the Danish Lung Cancer Registry, of whom 8758 were diagnosed at an early stage. Of those, 4071 (46%) were tested for EGFRm at diagnosis. Median OS was 5.7 years among patients with EGFRm‐positive status (n = 361) and 4.4 years among patients with EGFRm‐negative status (n = 3710). EGFRm‐positive status was associated with lower all‐cause mortality in all subgroups. This study contributes to population‐based evidence on the epidemiology of early‐stage NSCLC treated in routine clinical practice.Keywords
Funding Information
- AstraZeneca
This publication has 24 references indexed in Scilit:
- The Danish Lung Cancer RegistryClinical Epidemiology, 2016
- Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III TrialJournal of Clinical Oncology, 2015
- EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).2015
- The prevalence of EGFR mutations in non‐small cell lung cancer in an unselected Caucasian populationAPMIS, 2014
- The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort studyBMJ Open, 2013
- Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007Thorax, 2013
- Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillanceThe Journal of Thoracic and Cardiovascular Surgery, 2013
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clinic Proceedings, 2008